Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $30
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $21 to $30.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $21 to $30.